Belite Bio Scores First Successful Phase 3 Trial For Rare Vision-Loss Disease

BLTE's Tinlarebant trial showed significant efficacy in STGD1 patients. 35.7% lesion growth reduction confirmed compared to placebo in the trial. Company plans New Drug Application submission for Tinlarebant in 2026. BLTE stock rose 11.3% following the trial results announcement. RBP4 levels reduced by 80% at the trial's 5 mg daily dose.

Belite Bio's drug for genetic eye disease meets main goal in late-stage trial

Belite Bio's drug for rare eye disease achieved key goals in late-stage trial.

BLTE

BLTE price chart

Belite Bio Scores First Successful Phase 3 Trial For Rare Vision-Loss Disease

Belite Bio's drug for genetic eye disease meets main goal in late-stage trial

Company intelligence